Orserdu, a drug from Menarini Group subsidiary Stemline Therapeutics, is now approved for treating breast cancers that carry the ESR1 mutation. The drug is the first approved oral therapy from a class of therapies called selective estrogen receptor degraders (SERDs).
New York-based Stemline won Food and Drug Administration approval in December 2018 for Elzonris, a drug for blastic plasmacytoid dendritic cell neoplasm, or BPDCN, an extremely rare but aggressive form of leukemia.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
A biopharmaceutical company developing cancer therapies that zero in on cancer stem cells to treat brain cancer and acute myeloid leukemia is seeking to raise $50 million in an initial public offering. Cancer stem cells are viewed as highly malignant “seeds” of tumors, according to the company’s website. Although they account for 5 percent or […]